

Press release

Medios starts 2025 financial year successfully with significant increase in earnings

- Revenue up 6.2% to €484.7 million in the first quarter
- Significantly higher increase in EBITDA pre¹ of 52.9% to €23.1 million with margin improvement to 4.8%
- Earnings per share increased to €0.25 from €0.17 in Q1 2024
- 2025 forecast confirmed: Further revenue and earnings growth expected

Berlin, May 13, 2025 – The Medios-Group (“Medios” or “the Company”), a leading provider of Specialty Pharma in Europe, started the 2025 financial year with a positive performance in the first quarter and confirms its forecast for the full year. Revenue increased by 6.2% to €484.7 million compared to €456.2 million in Q1 2024. EBITDA pre¹ increased significantly by 52.9% to €23.1 million (Q1 2024: €15.1 million). Organic EBITDA pre¹ growth amounted to 4.6%. This resulted in an improvement in the EBITDA pre¹ margin of 1.5 percentage points to 4.8% (Q1 2024: 3.3%). Consolidated earnings after tax also improved significantly to €6.4 million (Q1 2024: €4.0 million), mainly due to the absence of one-off effects. Earnings per share thus rose to €0.25 (Q1 2024: €0.17).

The cash flow from operating activities in the reporting period was lower than in the same period of the previous year at €3.6 million (Q1 2024: €43.4 million) due to changes in net working capital as of the reporting date.

Matthias Gaertner, CEO of Medios AG: “We had a strong start to 2025. Revenue has grown once again, but our earnings have developed even more strongly – driven by positive momentum from all operating segments and our strategic focus on higher-margin products. As a result, we have already achieved our target margin for the full year in the first quarter and are continuing on our growth course.”

Increased earnings in all operating segments

The **Pharmaceutical Supply** segment posted revenue of €389.2 million in the first quarter of 2025 (Q1 2024: €401.0 million). EBITDA pre¹ for the division increased significantly by 7.0% to €11.8 million (Q1 2024: €11.0 million) as a result of the strategic focus on higher-margin products.

The **Patient-Specific Therapies** segment achieved a slight increase in revenue to €55.8 million in the first quarter of 2025 (Q1 2024: €55.1 million). EBITDA pre¹ for the segment improved by 6.4% to €6.3 million (previous year: €5.9 million).

The **International Business** segment, which comprises the activities of Ceban Pharmaceuticals B.V., included in the scope of consolidation since June 1, 2024, generated revenue of €39.5 million and EBITDA pre¹ of €7.3 million in the first quarter of 2025. The segment thus made a significant contribution to the positive performance of the Medios Group.

Positive outlook confirmed

Medios confirms its forecast for the 2025 financial year. The Company expects revenues to increase by around 6% to approx. €2 billion. EBITDA pre¹ is expected to increase again disproportionately by approx. 21.5% to around €96 million. This corresponds to a further increase in the EBITDA pre¹ margin to around 4.8%. This expectation is based on the assumption of organic growth in the mid-single-digit percentage range and takes into account the consolidation of the Ceban Group for twelve months.

Key figures (IFRS)

in € million

	Q1 2025	Q1 2024	Δ in %
Revenue	484.7	456.2	6.2
Pharmaceutical Supply	389.2	401.0	-2.9
Patient-Specific Therapies	55.8	55.1	1.3
International Business	39.5	0	n/a
Services	0.1	0.1	-4.1
EBITDA pre¹	23.1	15.1	52.9
Pharmaceutical Supply	11.8	11.0	7.0
Patient-Specific Therapies	6.3	5.9	6.4
International Business	7.3	0	n/a
Services	-2.4	-1.9	24.1
Consolidated earnings after tax	6.4	4.0	59.9
Cashflow from operating activities	3.6	43.4	-91.8
Earnings per share (in €)	0.25	0.17	47.1

The Medios Quarterly Statement as of March 31, 2025, will be available for [download](#) on the Investor Relations website.

Important dates for Medios in the 2025 financial year:

May 27	Ordinary Annual General Meeting 2025 (AGM)
June 11	Warburg Highlights – Hamburg
August 13	Half-Year Financial Report
August 26	German Select V Online Conference – virtually
September 24	Berenberg Fourteenth German Corporate Conference – Munich
November 11	Quarterly Statement as of September 30, 2025
December 04	Berenberg European Conference – Fairmont Windsor Park, UK

¹ EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjusted for special charges for stock options, expenses for M&A activities and, in 2023 and 2024, performance-related payments for the acquisition of compounding volumes. Since 2024, expenses for the implementation of the ERP system have also been included.

About Medios AG

Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the Company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

Medios AG is Germany's first listed specialty pharmaceutical Company. The shares are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.

www.medios.group

Contact

Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
ir@medios.group
www.medios.group



Disclaimer

This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Medios AG assumes no responsibility to update any forward-looking statements contained in this release.